Lutetium-177 (Lu-177) producer Shine Technologies has reached a long-term supply agreement with Nucleus RadioPharma, a development, manufacturing, and supply chain organization for radiopharmaceuticals.
Under the multiyear agreement, Shine will provide Lu-177 to Nucleus RadioPharma's radioligand therapy offerings for targeted radiopharmaceutical treatments for neuroendocrine tumors and prostate cancer. The partnership also ensures Nucleus will be supplied with the radioisotope required for their therapies in clinical trials as they investigate the efficacy of targeted radiopharmaceuticals in additional cancer types.
Shine recently opened its Wisconsin facility, Cassiopeia, dedicated to producing non-carrier-added Lu-177. Cassiopeia is expected to produce up to 200,000 doses per year of medical isotopes that are often in short supply.